Esperion Therapeutics, Inc.
ESPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $525 | $194 | $282 | $430 |
| - Cash | $92 | $86 | $115 | $145 |
| + Debt | $152 | $598 | $298 | $298 |
| Enterprise Value | $584 | $706 | $466 | $583 |
| Revenue | $87 | $82 | $65 | $69 |
| % Growth | 6% | 26.8% | -6% | – |
| Gross Profit | $32 | $54 | $33 | $43 |
| % Margin | 36.5% | 65.4% | 51.5% | 62.9% |
| EBITDA | -$9 | $8 | -$21 | -$5 |
| % Margin | -10.6% | 9.5% | -32.3% | -7% |
| Net Income | -$31 | -$13 | -$40 | -$21 |
| % Margin | -35.9% | -15.4% | -62.2% | -30.8% |
| EPS Diluted | -0.2 | -0.024 | -0.21 | -0.11 |
| % Growth | -726.4% | 88.5% | -90.9% | – |
| Operating Cash Flow | -$4 | -$31 | -$23 | -$35 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4 | -$31 | -$23 | -$35 |